P300/CBP Proteins: HATs for Transcriptional Bridges and Scaffolds
Overview
Authors
Affiliations
p300/CBP transcriptional co-activator proteins play a central role in co-ordinating and integrating multiple signal-dependent events with the transcription apparatus, allowing the appropriate level of gene activity to occur in response to diverse physiological cues that influence, for example, proliferation, differentiation and apoptosis. p300/CBP activity can be under aberrant control in human disease, particularly in cancer, which may inactivate a p300/CBP tumour-suppressor-like activity. The transcription regulating-properties of p300 and CBP appear to be exerted through multiple mechanisms. They act as protein bridges, thereby connecting different sequence-specific transcription factors to the transcription apparatus. Providing a protein scaffold upon which to build a multicomponent transcriptional regulatory complex is likely to be an important feature of p300/CBP control. Another key property is the presence of histone acetyltransferase (HAT) activity, which endows p300/CBP with the capacity to influence chromatin activity by modulating nucleosomal histones. Other proteins, including the p53 tumour suppressor, are targets for acetylation by p300/CBP. With the current intense level of research activity, p300/CBP will continue to be in the limelight and, we can be confident, yield new and important information on fundamental processes involved in transcriptional control.
Dysregulation of the p300/CBP histone acetyltransferases in human cancer.
Xu L, Xuan H, Shi X Epigenomics. 2025; 17(3):193-208.
PMID: 39929233 PMC: 11812348. DOI: 10.1080/17501911.2024.2447807.
Hu J, Tang X, Luo G, Zhang C, Wu T, Wang C Acta Pharmacol Sin. 2025; .
PMID: 39890943 DOI: 10.1038/s41401-025-01478-x.
Li W, Feng Y, Teng Y, Montero A, Zhou Y, Zhang X J Biol Chem. 2025; 301(2):108193.
PMID: 39826689 PMC: 11849104. DOI: 10.1016/j.jbc.2025.108193.
Targeting CBP and p300: Emerging Anticancer Agents.
Masci D, Puxeddu M, Silvestri R, La Regina G Molecules. 2024; 29(19).
PMID: 39407454 PMC: 11482477. DOI: 10.3390/molecules29194524.
Venhorst J, Hanemaaijer R, Dulos R, Caspers M, Toet K, Attema J Front Pharmacol. 2024; 15:1442752.
PMID: 39399467 PMC: 11466758. DOI: 10.3389/fphar.2024.1442752.